Randomized clinical trials in children - ethical and methodological issues

Current Pharmaceutical Design

Volumn 16, Issue 22, 2010, Pages 2407-2415

  Henschel, A D ^a   Rothenberger, L G ^a,b   Boos, J ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b Clinic for Psychosomatic Medicine   (Germany)

Author keywords

Children; Equipoise; Ethics; Randomization; Trial design

Indexed keywords

CHILD; CLINICAL RESEARCH; ETHICS; HUMAN; METHODOLOGY; PRIORITY JOURNAL; PUBLICATION; QUANTITATIVE ANALYSIS; RANDOMIZATION; REVIEW;

CHILD; ETHICS, MEDICAL; HUMANS; PUBLISHING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SERIAL PUBLICATIONS; THERAPEUTIC HUMAN EXPERIMENTATION;

EID: 77955641535     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791959854     Document Type: Review

References (46)

1. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. BMJ 1948; ii: 769-82.
2. Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-3.
3. Bjelakovic G, Nikolova D, Gluud LL, Somonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and metaanalysis. JAMA 2007; 297: 842-57.
4. Pine DS. Editorial: Where have all the clinical trials gone? J Child Psychol Psychiatry 2005; 46(5): 449-50.
5. Pine DS. Editorial: Evaluating new and old treatments for ADHD. J Child Psychol Psychiatry 2009; 50(7): 767-8.
6. Glasziou P, Chalmers I, Rawlins M, McCulloch P. When are randomised trials unnecessary? BMJ 2007; 334(7589): 349-51.
7. Smith GC, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ 2003; 327(7429): 1459-61.
8. Cochrane AL. Effectiveness and Efficiency: Random Reflections on Health Services. London: Nuffield Provincial Hospitals Trust, 1972; 20-5.
9. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [Accessed October 23, 2009]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
10. Kunz R, Vist GE, Oxman AD. Randomisation to protect against selection bias in healthcare trials. Cochrane Database of Systematic Reviews 2007, Issue 2. Art. No.: MR000012.
11. Haynes RB, Sackett DL, Guyatt GH, Tugwell P. Clinical epidemiology: how to do clinical practice research. Philadelphia, Lippincott, Williams and Wilkins 2006.
12. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chron Dis 1967; 20: 637 e48.
13. Karanicolas PJ, Montori VM, Devereaux PJ, Schünemann H, Guyatt GH. A new mechanistic-practical framework for designing and interpreting randomized trials. J Clin Epidemiol 2009; 62:479-84.
14. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22: 151-85.
15. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. http://www.wma.net/en/30publications/10policies/b3/index.html [Accessed October 12, 2009].
16. U.S. Department of Health, Education, and Welfare. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont report: Ethical principles and guidelines for the protection of human subjects of research. (April 1979) http://www.hhs.gov/ohrp/humansubjects/guidance/belmont.htm [Accessed October 10, 2009].
17. Beauchamp TL, Childress. Principles of Biomedical Ethics. New York/Oxford: University Press 2009.
18. Krugman S. Experiments at Willowbrook. Lancet 1971; 1: 1078-9.
19. Krugman S. The Willowbrook hepatitis studies revisited: ethical aspects. Rev Infect Dis 1986; 8: 157-62.
20. Sutherland JM. Toxicity of chloramphenicol for the newborn infant. Am J Dis Child 1959; 98: 64.
21. Mcbride WG. Thalidomide and congenital abnormalities. Lancet 1961; 278: 1358.
22. Conroy S, McIntyre J, Choonara I. Unlicensed and off label drug use in neonates. Arch Dis Child Fetal Neonatal Ed 1999; 80: F142-4.
23. Lindell-Osuagwu L, Korhonen MJ, Saano S, Helin-Tanninen M, Naaranlahti T, Kokki H. Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature. J Clin Pharm Ther 2009; 34(3): 277-87.
24. Shirkey H. Therapeutic orphans. J Pediatr 1968; 72: 119-20.
25. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol1_en.htm [Accessed December 9, 2009].
26. [European Medicines Agency. Assessment of the paediatric needs psychiatry. 27 July 2007. http://www.emea.europa.eu/pdfs/human/paediatrics/28891707en.pdf [Accessed December 10, 2009].
27. Seyberth HW. Pharmakologische Besonderheiten im Kinders- und Jugendalter. Brochhausen, Christoph/Seyberth, Hannsjörg W.: Kinder in klinischen Studien - Grenzen medizinischer Machbarkeit? Muenster: Lit 2005; pp. 37-54.
28. European union, ethical considerations for clinical trials on medicinal products conducted with the paediatric population. Eur J Health Law 2008; 15: 223-50.
29. Hoop JG, Smyth AC, Roberts LW. Ethical Issues in psychiatric research on children and adolescents. Child Adolesc Psychiatric Clin N Am 2008; 17:127-48.
30. Chiron C, Tonnelier S, Rey E, et al. Stiripentol in childhood partial epilepsy: randomized placebo-controlled trial with enrichment and withdrawal design. J Child Neurol 2006; 21(6): 496-502.
31. European Medicines Agency. Guideline On Clinical Trials In Small Populations. July 2006. http://www.emea.europa.eu/pdfs/uman/ewp/8356105en.pdf [Accessed October 26, 2009].
32. Sackett DL. Why randomized controlled trials fail but needn't: 1. Failure to gain "coal-face" commitment and to use the uncertainty principle. CMAJ 2000; 162(9):1311-4.
33. Freedman B. 'Equipoise and the ethics of clinical research'. N Engl J Med 1987; 317 (3): 141-5.
34. Edwards SJL, Lilford RJ, Braunholtz DA. Ethical issues in the design and conduct of randomised controlled trials. Health Technol Assess 1998; 2:i-vi, 1-132.
35. Hietanen P, Aro AR, Holli K, Absetz P. Information and communication in the context of a clinical trial. Eur J Cancer 2000; 36: 2096-104.
36. Featherstone K, Donovan JL. "Why don't they just tell me straight, why allocate it?" The struggle to make sense of participating in a randomised controlled trial. Soc Sci Med 2002; 55: 709-19.
37. Gotzsche PC. Multiple publication of reports of drug trials. Eur J Clin Pharmacol 1989; 36: 429-32.
38. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991; 337: 867-72.
39. Sammons HM, Atkinson M, Choonara I, Stephenson T. What motivates British parents to consent for research? A questionnaire study. BMC Pediatr 2007; 7:12.
40. Moher D, Schulz KF, Altman DG for the CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357: 1191-4.
41. International Committee of Medical Journal Editors. Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication. (Updated October 2008). http://www.icmje.org/urm_full.pdf [Accessed October 11, 2009].
42. Altman DG for the CONSORT Group. Endorsement of the CONSORT statement by high impact medical journals: survey of instructions for authors. BMJ 2005; 330:1056-7.
43. Scottish Intercollegiate Guidelines Network. A Guideline Developers' Handbook. Edinburgh: SIGN 2001, Revised 2008.
44. Maid G, Guerchicoff M, Falconi M, de Arenaza DP. Written consent to use the drug in children: the problem of off-label drugs. Curr Pharm Des 2008; 14(8): 776-781.
45. Seymour L. The design of clinical trials for new molecularly targeted compounds: progress and new initiatives. Curr Pharm Des 2002; 8(25): 2279-2284.
46. Vijverberg SJ, Pieters T, Cornel MC. Ethical and social issues in pharmacogenomics testing. Curr Pharm Des 2010; 16(2): 245-252.